Functional properties of factor V and factor Va encoded by the R2-gene

Thromb Haemost. 2001 Jan;85(1):75-81.

Abstract

Carriership of the factor V (FV) gene marked by the R2-haplotype, a series of linked polymorphisms encoding several amino acid changes in FV, is associated with mild resistance to activated protein C (APC) and with an increased risk of thrombosis. We compared the functional properties of normal FV(a) and R2-FV(a) in model systems and in plasma. FV and R2-FV were equally well activated by thrombin and expressed identical cofactor activities in prothrombin activation. Rate constants of APC-catalyzed inactivation of FVa and R2-FVa were similar both with and without protein S. However, significant differences were observed between haemostatic parameters determined in plasma from homozygous carriers of the R2-gene (n = 5) and age-matched non-carriers (n = 19). Plasma from R2-carriers contained significantly lower FV levels and the ratio of the two FV isoforms (FV1 and FV2) was shifted in favor of FV1. The FV2/FV1 ratio was 1.4 (95% CI = 1.3-1.5) in homozygous carriers of R2 and 2.8 (95% CI = 2.5-3.1) in controls (p < 0.00001). In an APC resistance test which quantifies the cofactor activity of FV in APC-catalyzed FVIII(a) inactivation, homozygous R2-carriers had significantly lower (p < 0.00001) APC sensitivity ratios (APCsr = 1.54, 95% CI = 1.48-1.60) than controls (APCsr = 2.17, 95% CI = 2.05-2.28). This indicates that R2-FV has reduced cofactor activity in APC-catalyzed FVIII(a) inactivation. The changes of the relative amounts of FV1 and FV2 in carriers of the R2-gene will result in increased thrombin formation in the presence of APC and may provide a mechanistic explanation for the increased thrombotic risk associated with the R2-haplotype.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activated Protein C Resistance / blood
  • Adult
  • Blood Coagulation Tests
  • Dose-Response Relationship, Drug
  • Factor V / genetics*
  • Factor V / metabolism
  • Factor V / physiology
  • Factor Va / genetics*
  • Factor Va / metabolism
  • Factor Va / physiology
  • Factor Xa / pharmacology
  • Female
  • Gene Expression Regulation / drug effects
  • Genotype
  • Haplotypes*
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Protein Isoforms / physiology
  • Protein S / pharmacology
  • Prothrombin / pharmacology
  • Thrombosis / etiology
  • Thrombosis / genetics

Substances

  • Protein Isoforms
  • Protein S
  • Factor Va
  • Factor V
  • Prothrombin
  • Factor Xa

Grants and funding